|
|
| (10 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| − | {{pnc}}
| |
| | | | |
| − | '''any'''
| |
| − | {{tp|p=32199615|t=ä. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses |pdf=|usr=}}
| |
| − | {{tp|p=32081428|t=2020. Structure analysis of the receptor binding of 2019-nCoV |pdf=|usr=}}
| |
| − | {{tp|p=32142651|t=2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor |pdf=|usr=}}
| |
| − | {{tp|p=32203189|t=ä. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine |pdf=|usr=}}
| |
| − | {{tp|p=32047258|t=ä. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein |pdf=|usr=}}
| |
| − | {{tp|p=32265513|t=ä. SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | '''ACE2'''
| |
| − | {{tp|p=32275855|t=ä. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2 |pdf=|usr=}}
| |
| − | {{tp|p=32279908|t=ä. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?|pdf=|usr=}}
| |
| − | {{tp|p=32251718|t=2020. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia |pdf=|usr=}}
| |
| − | {{tp|p=32201080|t=ä. Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32305506|t=ä. Renin-angiotensin system at the heart of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32291076|t=ä. EZH2-mediated H3K27me3 inhibits ACE2 expression |pdf=|usr=}}
| |
| − | {{tp|p=32299780|t=2020. Angiotensin-Converting Enzyme 2 as the Molecular Bridge Between Epidemiologic and Clinical Features of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32299779|t=ä. What is the Role of Angiotensin Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive, Diabetic Patients?|pdf=|usr=}}
| |
| − | {{tp|p=32227090|t=ä. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32301968|t=ä. Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications |pdf=|usr=}}
| |
| − | {{tp|p=32133153|t=2020. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations |pdf=|usr=}}
| |
| − | {{tp|p=32313207|t=ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor |pdf=|usr=}}
| |
| − | {{tp|p=32264791|t=2020. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2 |pdf=|usr=}}
| |
| − |
| |
| − | '''tmprss2'''
| |
| − |
| |
| − | ''others'''
| |
| − |
| |
| − | {{tp|p=32130973|t=2020. A potential role for integrins in host cell entry by SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32272173|t=2020. Coronavirus membrane fusion mechanism offers a potential target for antiviral development |pdf=|usr=}}
| |
| − | ----
| |
| − |
| |
| − | {{tp|p=32220422|t=2020. The hosts angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections |pdf=|usr=}}
| |
| − | {{tp|p=32336612|t=ä. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32210742|t=2020. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis |pdf=|usr=}}
| |
| − | {{tp|p=32327200|t=ä. Covid-19 and the angiotensin-converting enzyme (ACE2): Areas for research |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=32344526|t=2020. COVID-19 and RAS: Unravelling an Unclear Relationship |pdf=|usr=}}
| |
| − | {{tp|p=32274964|t=2020. A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin |pdf=|usr=}}
| |
| − | {{ttp|p=32169481|t=2020. COVID-19 spike-host cell receptor GRP78 binding site prediction |pdf=|usr=}}
| |
| − | {{tp|p=32092392|t=2020. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV |pdf=|usr=}}
| |
| − |
| |
| − | {{tp|p=31996437|t=2020. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus |pdf=|usr=}}
| |
| − | {{ttp|p=31826992|t=2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |pdf=|usr=}}''antibodies target one serotype of viruses but only subneutralize another, leading to antibody-dependend enhancement of the latter viruses.''
| |
| − |
| |
| − | {{tp|p=32199943|t=ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{ttp|p=32362314|t=ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |pdf=|usr=}}
| |
| − | {{tp|p=32221306|t=2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV |pdf=|usr=}}
| |
| − | {{tp|p=32094589|t=ä. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses |pdf=|usr=}}
| |
